These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 18320294)
1. Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes. Dicko A; Frazier AA; Liboiron BD; Hinderliter A; Ellena JF; Xie X; Cho C; Weber T; Tardi PG; Cabral-Lilly D; Cafiso DS; Mayer LD Pharm Res; 2008 Jul; 25(7):1702-13. PubMed ID: 18320294 [TBL] [Abstract][Full Text] [Related]
2. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Tardi PG; Gallagher RC; Johnstone S; Harasym N; Webb M; Bally MB; Mayer LD Biochim Biophys Acta; 2007 Mar; 1768(3):678-87. PubMed ID: 17208196 [TBL] [Abstract][Full Text] [Related]
3. Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. Dicko A; Tardi P; Xie X; Mayer L Int J Pharm; 2007 Jun; 337(1-2):219-28. PubMed ID: 17270372 [TBL] [Abstract][Full Text] [Related]
4. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044 [TBL] [Abstract][Full Text] [Related]
5. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Ramsay E; Alnajim J; Anantha M; Taggar A; Thomas A; Edwards K; Karlsson G; Webb M; Bally M Pharm Res; 2006 Dec; 23(12):2799-808. PubMed ID: 17063397 [TBL] [Abstract][Full Text] [Related]
6. The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™. Patankar N; Anantha M; Ramsay E; Waterhouse D; Bally M Pharm Res; 2011 Apr; 28(4):848-57. PubMed ID: 21181548 [TBL] [Abstract][Full Text] [Related]
7. Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl. Shende P; Gaud R Drug Dev Ind Pharm; 2009 May; 35(5):612-8. PubMed ID: 18951273 [TBL] [Abstract][Full Text] [Related]
8. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. Ramsay E; Alnajim J; Anantha M; Zastre J; Yan H; Webb M; Waterhouse D; Bally M Eur J Pharm Biopharm; 2008 Mar; 68(3):607-17. PubMed ID: 17904831 [TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Batist G; Gelmon KA; Chi KN; Miller WH; Chia SK; Mayer LD; Swenson CE; Janoff AS; Louie AC Clin Cancer Res; 2009 Jan; 15(2):692-700. PubMed ID: 19147776 [TBL] [Abstract][Full Text] [Related]
10. Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67. Joguparthi V; Xiang TX; Anderson BD J Pharm Sci; 2008 Jan; 97(1):400-20. PubMed ID: 17879989 [TBL] [Abstract][Full Text] [Related]
11. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice. Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139 [TBL] [Abstract][Full Text] [Related]
12. Incompatibility between irinotecan and fluorouracil injections. Tan X; Hu J Am J Health Syst Pharm; 2016 Jun; 73(11):755. PubMed ID: 27208061 [No Abstract] [Full Text] [Related]
13. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Dicko A; Kwak S; Frazier AA; Mayer LD; Liboiron BD Int J Pharm; 2010 May; 391(1-2):248-59. PubMed ID: 20156541 [TBL] [Abstract][Full Text] [Related]
14. [Weekly low dose CPT-11 for multiple lung metastases of colon cancer on an out-patient treatment: a case report]. Sasaki K; Takasaka H; Kawasaki H; Oono K; Nakayama I; Matsunaga T; Takaoka A; Aoki S; Hamamatsu C; Hirayama T; Nakagawa N; Shibata K; Yabana T; Yamamoto Y; Hirata K Nihon Shokakibyo Gakkai Zasshi; 2001 Feb; 98(2):157-61. PubMed ID: 11235190 [No Abstract] [Full Text] [Related]
15. Formulation and in vitro characterization of thermosensitive liposomes for the delivery of irinotecan. Casadó A; Sagristá ML; Mora M J Pharm Sci; 2014 Oct; 103(10):3127-38. PubMed ID: 25091422 [TBL] [Abstract][Full Text] [Related]
16. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release. Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336 [TBL] [Abstract][Full Text] [Related]